AI agents are the fastest-growing and least-governed class of these machine identities — and they don’t just authenticate, ...

One analyst sees significant upside for the stock after yesterday's sell-off.

Measuring treatment success in Sjögren's disease requires more than tracking systemic disease activity alone. Fatigue, pain, ...

Explore the challenges faced by Indian pharma in developing rare disease drugs and potential solutions for innovation and cost reduction.

Two phase III studies of setrusumab, Orbit and Cosmic, for treating brittle bones have failed and left the developers floundering on Wall Street. Neither of Ultragenyx Pharmaceutical Inc. and Mereo ...

Composite endpoints are widely used in large randomised cardiovascular outcome trials. They are frequently referred to as ...

Shares of Ultragenyx and Mereo BioPharma were rocked by disappointing late-stage trial results of their brittle-bone disease treatment. It's looking like a poor end to 2025 for investors in two ...

The company said results from the Phase 3 Orbit and Cosmic studies with Mereo BioPharma for setrusumab, also referred to as UX143, in osteogenesis imperfecta didn't achieve statistical significance ...

Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.

Objective Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the ...

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...